[
  {
    "ts": null,
    "headline": "Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference",
    "summary": "Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference in Las Vegas from September 2-5, 2025.",
    "url": "https://finnhub.io/api/news?id=6afa3f8c1a33a4dd80d46efa67fbe634e8867b68216bcf8dbc3eb5cd3443952a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754056800,
      "headline": "Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference",
      "id": 136166035,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference in Las Vegas from September 2-5, 2025.",
      "url": "https://finnhub.io/api/news?id=6afa3f8c1a33a4dd80d46efa67fbe634e8867b68216bcf8dbc3eb5cd3443952a"
    }
  }
]